Skip to content

Bronchoscopic Vapour Therapy for Emphysema (Phase 2)

Australia Phase 2 Safety and Efficacy Study of Bronchoscopic Thermal Vapour Ablation (BTVA) for Lung Volume Reduction in Patients with Heterogeneous Emphysema with Upper Lobe Predominance (Bilateral)

Status
Suspended
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12608000505303
Enrollment
30
Registered
2008-09-30
Start date
2008-11-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of this study is to evaluate the safety and effectivness of a bilateral application of bronchoscopic thermal vapour ablation (BTVA) for lung volume reduction in patients diagnosed with heterogeneous upper lobe emphysema.

Interventions

Vapour (steam) is infused into a targeted emphysematous lung segment for approximately 3 - 10 seconds. Up to 7 lung segments within the right and left upper lobes of the lung will be treated in one procedure. Patients in the first cohort will receive a prescribed amount of vapour (target vapour dose) delivered to each lung segment of 7.5 calories per gram of lung tissue. A second cohort of patients may be treated with a target vapour dose of 10 calories per gram of lung tissue after 3 month f

Vapour (steam) is infused into a targeted emphysematous lung segment for approximately 3 - 10 seconds. Up to 7 lung segments within the right and left upper lobes of the lung will be treated in one procedure. Patients in the first cohort will receive a prescribed amount of vapour (target vapour dose) delivered to each lung segment of 7.5 calories per gram of lung tissue. A second cohort of patients may be treated with a target vapour dose of 10 calories per gram of lung tissue after 3 month follow-up results are reviewed.

Sponsors

Uptake Medical Corp.
Lead SponsorCommercial sector/Industry

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Heterogeneous emphysema with upper lobe predominance confirmed by computerized tomography (CT) and quantitative differential ventilation and perfusion scan; Able to walk at least 140 meters; non-smoking for 3 months prior to study enrollment; completed pulmonary rehabilitation program

Exclusion criteria

Known alpha 1 antitrypsin deficiency; previous heart or lung transplant or lung; previous history of unstable myocardial ischemia; FEV1 < 15%

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026